Introduction {#Sec1}
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Follicular thyroid carcinoma (FTC) today accounts for about 10 % of all thyroid cancers in iodine-sufficient populations \[[@CR1]\]. Together with papillary thyroid carcinoma (PTC), by far the most common thyroid malignancy, FTC constitutes the so-called differentiated thyroid cancers of follicular origin. It is more common in women and its highest incidence is reported to be shortly after menopause \[[@CR2]--[@CR4]\]. FTC is generally subdivided into widely and minimally invasive FTC (WI-FTC and MI-FTC) \[[@CR5]\]. MI-FTC is limited to microscopic capsular and/or vascular invasion, described in the WHO classification \[[@CR5]\] as "focal, minimal, a focus, limited, a single focus", whereas widely invasive is described as "extensive, widespread invasion, multifocal areas, multiple foci and extensively invaded". FTC is generally considered to have a good prognosis, especially in young patients \[[@CR6]\]. This is particularly true for MI-FTC \[[@CR2], [@CR6]\]. Despite this, some cases metastasise and/or develop local recurrence \[[@CR2], [@CR4]\].

As the diagnostic criteria are based on histopathology \[[@CR5]\], FTC cannot be differentiated from follicular thyroid adenoma by fine needle aspiration. Some molecular alterations could aid in differentiating between FTC and PTC. The *PAX8/PPARγ* rearrangements is found exclusively in follicular neoplasms, while the *RET/PTC* rearrangements are exclusive for PTC \[[@CR7]--[@CR9]\]. *PAX8/PPARγ* rearrangements, RAS mutations and *TERT* promoter mutations are recurrently seen in both MI-FTC and WI-FTC \[[@CR10], [@CR11]\]. In addition some genetic alterations, e.g. loss of heterozygosity for *HGF,* have been observed in MI-FTC only \[[@CR12]\]. The treatment of MI-FTC is still debated; many advocate lobectomy only, mainly to reduce surgical complications \[[@CR3], [@CR6]\]. A further subdivision of MI-FTC into cases with capsular invasion only and those with vascular invasion has been proposed, but previous studies have been contradictory \[[@CR3], [@CR6], [@CR13]\]. Although novel data may aid in the preoperative decision-making, we today have no sufficient tools to discriminate those patients that would benefit from more extensive treatment, although new molecular panels for fine needle aspirates have been proposed \[[@CR14]\]. Still, several clinical features should be taken into account for the individual patient \[[@CR15]\].

The aim of this study was to characterise the prognosis of patients with an initial diagnosis of MI-FTC and to identify prognostic parameters to facilitate clinical decision-making for adequate treatment and follow-up.

Materials and methods {#Sec2}
=====================

Databases from the Department of Surgery and Department of Pathology together with histopathological reports were used to identify all cases of minimally invasive FTC (MI-FTC) operated between 1986 and 2009 at the Karolinska University Hospital, Sweden. The tumours were re-classified according to the most recent WHO criteria \[[@CR5]\] by one pathologist. Only FTCs with limited capsular invasion and/or limited vascular invasion were selected. Patients with atypical follicular adenomas, WI-FTC, follicular variant of PTCs, or poorly differentiated (insular) tumours were excluded. Metastasis at the time of diagnosis was not an exclusion criterion, provided the FTC was classified as MI-FTC on the basis of the thyroid specimen per se.

Fifty-nine patients with MI-FTC were identified. One was lost to follow-up due to emigration shortly after surgery. All clinical data and histopathology reports of the remaining 58 cases were re-evaluated and collected for analysis. Patient and treatment data, tumour size, invasion pattern and tumour type were recorded. Presence of \>75 % oncocytic cells was the prerequisite for diagnosis of oncocytic tumours (i.e. Hürthle cell carcinoma). Proliferation data (determined by immunohistochemical analysis of Ki-67) was available for cases operated after 2002 only, and was therefore not included in the analysis. The type of surgery was registered as total thyroidectomy or lobectomy, where supplementary lobectomy within a month after the original operation was classified as total thyroidectomy. If tumour cells were found anywhere at the tumour resection margin upon histopathological examination, the resection was judged to be microscopically non-radical. Thyrotropin (TSH) suppressive treatment with thyroxin, adjuvant treatment with radioactive iodine, presence of lymphatic spread and distant metastatic disease at diagnosis, as well as recurrent disease, both local and metastatic, were recorded. The decision on the extent of the surgical procedure and adjuvant treatment did not follow a distinct protocol; it followed the judgement of the responsible clinician during the study period. Follow-up time was calculated from the time of the primary operation until September 2015 with the exception of one patient, who was followed until emigration in 2002.

The study was approved by the local ethics committee. All patients gave their informed consent for collection and analysis of tissue material and clinical data at the time of treatment.

Statistical analysis {#Sec3}
====================

Statistical analysis was performed with the IBM SPSS Statistics 23.0. 0.0 (Armonk, NY, USA). Data are expressed as median and range. The primary endpoint was death from FTC. Analysis of survival and prognostic significance of clinical parameters were performed with the Kaplan--Meier method and the log-rank test. *P* values ≤0.05 were considered statistically significant. The Cox regression model was used for multivariate analysis to identify independent prognostic factors \[[@CR16]\].

Results {#Sec4}
=======

Clinical, histopathological and follow-up data for the 58 patients with MI-FTC are summarised in Table [1](#Tab1){ref-type="table"}. *P* values obtained from the statistical analysis of death rates are included. Of the 58 patients, 41 were women (71 %) and 17 men (29 %), with a median age at diagnosis of 50 (range 11--92) years and a median tumour size of 35 (range 10--80) mm. Vascular invasion was observed in 36 cases (62 %) and was associated with larger tumour size \[median 40 (range 20--76) compared with 24 (10--80) mm for patients with capsular invasion only; *P* = 0.001\] and older patients \[54 (20--92) vs. 44 (11--77) years.; *P* = 0.019\]. Isolated capsular invasion was observed in 22 cases (38 %) and isolated vascular invasion in 5 cases (9 %).Table 1Patients with minimally invasive follicular thyroid cancer, clinical characteristics and analysis of the significance of mortality related to thyroid cancerParameter (no. of informative)Cases observedDeath rate^a^*P* valueNo.(%)No.(%)Log-rank testAge at surgery (*n* = 58) ≥50 years29505170.023 \<50 years295000Gender (*n* = 58) Female4171120.005 Male1729424Tumour size (*n* = 58) \<20 mm47000.820 20--40 mm3764411 \>40 mm172916Hürthle (*n* = 58) Yes1831000.133 No4069522Capsular and vascular invasion (*n* = 58) Yes30525170.034 No284800Capsular invasion (*n* = 58) Yes5391590.457 No5900Vascular invasion (*n* = 58) Yes36625140.085 No223800Surgical margin (microscopical) (*n* = 58) Radical5697470.080 Non-radical23150Operation type (*n* = 58) Lobectomy3052130.176 Total thyroidectomy2848414Ablative treatment (*n* = 57) Given18324220.023 Not given396813TSH suppressive treatment (*n* = 57) Given4579370.781 Not given1221217Recurrence (*n* = 58) Total595100 Metastases595100 Loco-regional121100Mortality (*n* = 58) Dead from disease59 Dead from other causes814^a^Death rate refers to patients who died from FTC

Twenty-eight patients (48 %) underwent total thyroidectomy; the rest underwent lobectomy. Total thyroidectomy was more common among patients with vascular invasion (21/36 compared to 7/22 with capsular invasion only; *P* = 0.045). Eighteen of 57 patients (32 %) with available data on adjuvant treatment had received ablation of the thyroid remnant together with radioactive iodine therapy; 45/57 patients (79 %) had received TSH suppressive treatment at least 5 years post-operatively.

The median follow-up time was 140 (21--308) months. Eight patients died from causes other than FTC and had no signs of recurrence, with a median follow-up of 140 (21--176) months. Five patients died from FTC after a median follow-up of 114 (41--193) months. The median age at diagnosis was 57 years (51--72) for these patients; median tumour size was 35 (30--50) mm. The patients who died from FTC all presented with tumours exhibiting both vascular and capsular invasion (Fig. [1](#Fig1){ref-type="fig"}a). All developed recurrent disease; two of them were diagnosed with distant metastasis already at the time of diagnosis. No patient had signs of lymphatic spread. Four of these five patients had undergone total thyroidectomy and one of them was classified as microscopically non-radical (tumour cells found in the resection margin).Fig. 1Kaplan--Meier plot illustrating disease-related survival related to combined vascular and capsular invasion among the 58 MI-FTC patients (**a**) and among the subgroup with non-Hürthle cell carcinoma (**b**). *Short vertical lines* indicate censored individuals. *P* values were calculated using the log-rank test. Below each panel is detailed the number of patients at diagnosis (0 m) and at different time-points during follow-up (60, 120, 180 and 240 months)

Univariate analysis identified male gender (*P* = 0.005), age at surgery ≥50 years (*P* = 0.023) and co-existing capsular and vascular invasion (*P* = 0.034) as related to postoperative metastatic disease and death from this disease. Gender was the only independent prognostic covariate when applying multivariate analysis (*P* = 0.035). No patient with tumours predominantly consisting of oncocytic cells (Hürthle cell carcinomas; *n* = 18) died from the disease and all but one were alive at the end of the follow-up. Exclusion of the Hürthle cell carcinomas did not alter the outcome of the univariate analyses (Fig. [1](#Fig1){ref-type="fig"}b).

Discussion {#Sec5}
==========

Many protocols advocate treatment of MI-FTC by total thyroidectomy and ablative radioiodine, as this is the most effective strategy for detecting recurrent and/or metastatic disease \[[@CR17], [@CR18]\]. This strategy allows detection of otherwise invisible metastases by whole-body scintigraphy and thyroglobulin measurements, as well as early detection of recurrent disease. FTCs of Hürthle cell type are also usually treated by total thyroidectomy, based on observations of worse prognosis and sometimes less iodine uptake in many series \[[@CR19]\]. Still, the superiority of this strategy has not yet been demonstrated in randomised studies; in the present study we rely on retrospective cohort data and consensus statements \[[@CR17]--[@CR22]\]. The optimal treatment of MI-FTC is more often a matter for discussion, as many series show excellent outcome also after lobectomy only \[[@CR3]\]. In this series of MI-FTC, no specific treatment protocol was applied. However, significantly more patients with vascular invasion were treated by total thyroidectomy. Subsequently, patients with tumours showing vascular invasion more often received radioactive iodine ablation. Hence, clinical decision-making was often based on the presence of vascular invasion. Still, this more extensive treatment was not found to improve the outcome. Today, the National Swedish Guidelines, which are based on the ETA Guidelines, call for surgical treatment by total thyroidectomy of all FTCs \[[@CR17], [@CR23]\]. Based on our observations and the available literature, we propose that the rationale for treating MI-FTC with isolated capsular invasion by total thyroidectomy could be questioned.

In this retrospective study, we confirm some results from other studies of MI-FTC (Table [2](#Tab2){ref-type="table"}). Many of the poor prognostic factors co-vary, making it difficult to identify single factors. In our study, no patient under the age of 50 at the time of diagnosis died from the disease. Also, all patients with tumours smaller than 3 cm survived. All five patients who died from the disease had tumours with both capsular and vascular invasion. Isolated capsular invasion fulfils the criteria for MI-FTC but still seems to correlate to an indolent prognosis. However, in a recent study, based on 251 patients with MI-FTC followed for median 7.2 years, distant metastases were observed in 12 % of patients with capsular invasion only \[[@CR22]\]. It should, however, be stressed that the diagnostic evaluation of follicular thyroid neoplasias requires a stringent macroscopic evaluation of the tumour, and gross handling of the specimen demands the acquisition of multiple sections of the tumour capsule. As all patients in our series who succumbed to FTC displayed evidence of both limited vascular and capsular invasion, one cannot entirely rule out the possibility that these tumours did in fact display widely invasive behaviour, although not adequately represented in the blocks obtained. The extent of surgery and radioiodine ablation did not affect the prognosis. Concordant with our findings, age at diagnosis and the existence of metastatic disease were identified as important prognostic factors.Table 2Minimally invasive follicular thyroid cancer (MI-FTC) outcome and prognostic factors implicated in this and in relevant studiesFirst author/year/ref*N*Geographical regionFollow-up (years)Outcome DM/MetSummary of resultsThis study58Sweden11.75/5Risk of death from MI-FTC related to combined capsular and vascular invasion, age at surgery ≥50 years and male genderThompson et al. /2001/\[[@CR3]\]95US16.54/1The prognosis of MI-FTC is excellent and lobectomy is sufficient for initial surgical managementO'Neill et al. /2011/\[[@CR20]\]98Australia3.37/1Risk is related to age; vascular invasion is a risk factor; hemithyroidectomy is adequate for patients \<45 yearsSugino et al./2012/\[[@CR22]\]251Japan7.254/14Risk of death from MI-FTC is related to age ≥45 years and tumour size ≥4 cmGoffredo et al. /2013/\[[@CR25]\]1200US16.86/2Neither extent of surgery nor radioiodine treatment had any impact on survival; thyroid lobectomy is adequate*N* number of MI-FTC cases, *DM* distant metastases, *DFS* death from disease

In this study, it is not possible to judge the effects of adjuvant treatment as those receiving radioiodine were a selected group of patients. Four of the five patients who died from MI-FTC had received ablative therapy. Among these, one patient treated with thyroidectomy was not radically operated, judging from the histopathological report. One may postulate that radioactive ablation does not replace the need for radical surgery. In a previous population-based nested case--control study of 1159 patients with differentiated thyroid cancer, half of whom died from their disease, we showed that radical removal of the primary tumour was an important prognostic factor \[[@CR24]\]. However, the type or extent of surgery and postoperative radioiodine did not influence survival \[[@CR24], [@CR26]\]. Recent data from the SEER's database indicate that patients with MI-FTC have survival comparable to that of the normative U.S. general population \[[@CR25]\]. However, this database does not provide detailed information on histopathological and clinical characteristics. The study's conclusion that MI-FTC can be treated as a benign lesion is challenged by the present and other studies \[[@CR20], [@CR22]\]. We instead propose that treatment should be modified based on the presence of vascular invasion, at least in elderly patients.

Surprisingly, all patients with Hürthle cell MI-FTC did well, although they are too few to support any distinct conclusions. Still, exclusion of these patients from the analysis did not alter the outcome (data not shown).

In conclusion, this study indicates that MI-FTC should not be regarded as an entirely indolent tumour. This is especially true for tumours with combined vascular and capsular invasion in patients over 50 years of age at diagnosis. The extent of the surgical procedure seems to be of less prognostic importance. Modification of the surgical strategy should rely on prognostic features.
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